Paralysis following spinal cord injury (SCI) is due to interruption of axons and their failure to regenerate. It has been suggested that the small GTPase RhoA may be an intracellular signaling convergence point for several types of growth-inhibiting extracellular molecules. Even if this is true in vitro, it is not clear from studies in mammalian SCI, whether the effects of RhoA manipulations on axon growth in vivo are due to a RhoA-mediated inhibition of true regeneration or only of collateral sprouting from spared axons, since work on SCI generally is performed with partial injury models. RhoA also has been implicated in local neuronal apoptosis after SCI, but whether this reflects an effect on axotomy-induced cell death or an effect on other pathological mechanisms is not known. In order to resolve these ambiguities, we studied the effects of RhoA knockdown in the sea lamprey central nervous system (CNS), where after complete spinal cord transection (TX), robust but incomplete regeneration of large axons belonging to individually identified reticulospinal (RS) neurons occurs, and where some RS neurons show unambiguous delayed retrograde apoptosis after axotomy. RhoA protein was detected in neurons and axons of the lamprey brain and spinal cord, and its expression was increased post-TX. Knockdown of RhoA in vivo by retrogradely-delivered morpholino antisense oligonucleotides (MOs) to the RS neurons significantly reduced retrograde apoptosis signaling in identified RS neurons post-SCI, as indicated by Fluorochrome Labeled Inhibitor of Caspases (FLICA) in brain wholemounts. In individual RS neurons, the reduction of caspase activation by RhoA knockdown began at 2 weeks post-TX and was still seen at 8 weeks. RhoA knockdown slowed axon retraction and possibly increased early axon regeneration in the proximal stump. The number of axons regenerating beyond the lesion more than 5 mm at 10 weeks post-TX also was increased. Thus RhoA knockdown both enhanced true axon regeneration and inhibited retrograde apoptosis signaling after SCI.
After spinal cord injury (SCI), axon regeneration is inhibited by several types of inhibitory molecules, such as the chondroitin sulfate proteoglycans (CSPGs), myelin-associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (Omgp), Nogo, and their corresponding receptors (Yiu and He, 2006; Ferguson and Son, 2011) . Accumulating evidence suggests that the intracellular signaling pathways for inhibition of axon growth by both CSPGs and CNS myelin proteins converge on the small GTPase RhoA, which makes it a potential therapeutic target (Monnier et al., 2003; Fu et al., 2007; Fisher et al., 2011) , whose inhibition might produce stronger therapeutic effects on axon regeneration than manipulating single inhibitory molecules.
In primary neuronal cultures, inactivation of Rho with C3 transferase (C3), or of its downstream target Rho kinase (ROCK) with Y-27632, has enhanced neurite growth on myelin or CSPG substrates (Lehmann et al., 1999; Dergham et al., 2002; Fournier et al., 2003; Monnier et al., 2003; Bertrand et al., 2005) . Consistently, ROCKII(−/−) dorsal root ganglion neurons (DRGs) are less sensitive to inhibition by Nogo or by CSPGs (Duffy et al., 2009 ) than wild type DRGs. Rho inactivation in retinal ganglion cells (RGCs) either at the lesion site or in the cell body promoted crushed optic nerves to regrow across the lesion (Lehmann et al., 1999; Bertrand et al., 2005) . In ROCKII (−/−) mice, after dorsal root crush, axons regenerated across the dorsal root entry zone (DREZ) into the spinal cord (Duffy et al., 2009) . Moreover, in mouse and rat, both neurons and glial cells showed activation of Rho at the site of SCI (Dubreuil et al., 2003) . In rats, RhoA-positive cells accumulated at day 1 after injury, reached maximum levels at day 3, and remained significantly elevated until 4 weeks (Conrad et al., 2005) . Either C3 or Y-27632 treatment was sufficient to promote functional recovery and growth of corticospinal tract (CST) fibers beyond a partial SCI in mice (Dergham et al., 2002; Boato et al., 2010) . Enhanced CST axon growth Neurobiology of Disease 98 (2017) [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 
